Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

Réseaux Appels à projets Actualités
430 publications
Année de publication :
Réseaux :

Stratifying patients with intermediate-risk prostate cancer.

Objective: Intermediate-risk prostate cancer regroups heterogeneous patients with different oncologic outcomes. Aim of the study is to validate a novel intermediate-risk subclassification (« magnetic resonance imaging [MRI] subclassification ») that defines favorable and unfavorable diseases based on multiparametric MRI parameters and compare it to NCCN and AUA intermediate-risk subclassifications.

  • Ref: Urol Oncol. 2020 Oct 8:S1078-1439(20)30399-9.
  • Année de publication : 2020
  • Auteurs : Diamand R, Ploussard G, Roumiguié M, Malavaud B, Oderda M, Gontero P, Fourcade A, Fournier G, Benamran D, Iselin C, Fiard G, Descotes JL, Peltier A, Simone G, Roche JB, Roumeguère T, Albisinni S.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Planning With Patient-Specific Rectal Sub-Region Constraints Decreases Probability of Toxicity in Prostate Cancer Radiotherapy.

Background: A rectal sub-region (SRR) has been previously identified by voxel-wise analysis in the inferior-anterior part of the rectum as highly predictive of rectal bleeding (RB) in prostate cancer radiotherapy.

  • Ref: Front Oncol. 2020 Sep 11;10:1597.
  • Année de publication : 2020
  • Auteurs : Lafond C, Barateau A, N'Guessan J, Perichon N, Delaby N, Simon A, Haigron P, Mylona E, Acosta O, de Crevoisier R.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization…

In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge.

  • Ref: Radiology. 2020 Sep;296(3):673-684.
  • Année de publication : 2020
  • Auteurs : Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; SARAH Trial Group.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

PTPN11 mutations in canine and human disseminated histiocytic sarcoma.

In humans, histiocytic sarcoma (HS) is an aggressive cancer involving histiocytes. Its rarity and heterogeneity explain that treatment remains a challenge.

  • Ref: Int J Cancer. 2020 Sep 15;147(6):1657-1665.
  • Année de publication : 2020
  • Auteurs : Hédan B, Rault M, Abadie J, Ulvé R, Botherel N, Devauchelle P, Copie-Bergman C, Cadieu E, Parrens M, Alten J, Zalcman EL, Cario G, Damaj G, Mokhtari K, Le Loarer F, Coulomb-Lhermine A, Derrien T, Hitte C, Bachelot L, Breen M, Gilot D, Blay JY, Donadieu J, André C.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

Antibody-Drug Conjugates: The Last Decade.

An armed antibody (antibody-drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years.

  • Ref: Pharmaceuticals (Basel). 2020 Sep 14;13(9):245.
  • Année de publication : 2020
  • Auteurs : Joubert N, Beck A, Dumontet C, Denevault-Sabourin C.
  • Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »
Lire la publication

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.

Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46) showed reduced performance in men with African genetic ancestry.

  • Ref: Int J Cancer. 2020 Sep 15.
  • Année de publication : 2020
  • Auteurs : Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K; UKGPCS Collaborators, Lophatananon A, Tangen CM, Goodman PJ, Thompson IM Jr, Blot WJ, Zheng W, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Park JY, Lin HY, Bensen JT, Fontham ETH, Mohler JL, Taylor JA, Multigner L, Blanchet P, Brureau L, Romana M, Leach RJ, John EM, Fowke J, Bush WS, Aldrich M, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Parent MÉ, Hu JJ, Sanderson M, Mills IG, Andreassen OA, Dale AM, Seibert TM; PRACTICAL Consortium.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection.

Context: Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear.

  • Ref: Eur Urol Oncol. 2020 Oct;3(5):565-581.
  • Année de publication : 2020
  • Auteurs : Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G; EAU-YAU Prostate Cancer Working Party.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Neurofibromin Structure, Functions and Regulation.

Neurofibromin is a large and multifunctional protein encoded by the tumor suppressor gene NF1, mutations of which cause the tumor predisposition syndrome neurofibromatosis type 1 (NF1).

  • Ref: Cells. 2020 Oct 27;9(11):E2365.
  • Année de publication : 2020
  • Auteurs : Bergoug M, Doudeau M, Godin F, Mosrin C, Vallée B, Bénédetti H.
  • Réseaux : Réseaux: « Molécules Marines, Métabolisme et Cancer »
Lire la publication

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.

Among myeloproliferative neoplasms, polycythemia vera (PV) and essential thrombocythemia (ET) are the 2 entities associated with the most chronic disease course. Leukemic evolution occurs rarely but has a grim prognosis.

  • Ref: Blood Adv. 2020 Oct 13;4(19):4887-4897.
  • Année de publication : 2020
  • Auteurs : Luque Paz D, Jouanneau-Courville R, Riou J, Ianotto JC, Boyer F, Chauveau A, Renard M, Chomel JC, Cayssials E, Gallego-Hernanz MP, Pastoret C, Murati A, Courtier F, Rousselet MC, Quintin-Roué I, Cottin L, Orvain C, Thépot S, Chrétien JM, Delneste Y, Ifrah N, Blanchet O, Hunault-Berger M, Lippert E, Ugo V.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication